Piezo Motion Announces a Partnership to Expand Its Disruptive Precision Motor Technology
03 févr. 2022 08h00 HE
|
Brain Scientific Inc.
LAKEWOOD RANCH, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, and Applied Mechatronics today announce a partnership. Piezo Motion...
Revolution Medicines to Provide R&D Update, Including Expansion of Development-Stage RAS(ON) Inhibitor Pipeline, During Presentation at 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted...
Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
24 nov. 2021 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
08 nov. 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
03 nov. 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Phoenix Specialty Manufacturing Is Helping Customers Reduce Supply Chain Risk
07 oct. 2021 13h00 HE
|
Phoenix Specialty Manufacturing Co.
BAMBERG, S.C., Oct. 07, 2021 (GLOBE NEWSWIRE) -- As the manufacturing supply chain continues to experience the pain associated with shipping delays, material shortages and significant inflation,...
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
15 sept. 2021 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
11 août 2021 16h01 HE
|
Revolution Medicines, Inc.
Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic Initial Results of RMC-4630-02 Study...
Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
04 août 2021 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...